EC Number   |
Disease |
PubMed ID |
Title of Publication  |
Category |
Confidence Level |
|---|
   3.4.24.46 | Neoplasms |
14598310 |
ADAMs family members as amyloid precursor protein alpha-secretases. |
causal interaction
therapeutic application
unassigned |
1
4
0 |
| 3.4.24.46 | Neoplasms |
19718658 |
Alternative splicing of ADAM15 regulates its interactions with cellular SH3 proteins. |
causal interaction
unassigned |
1
0 |
| 3.4.24.46 | Melanoma |
26072417 |
Antiangiogenic Metargidin Peptide (AMEP) Gene Therapy in Disseminated Melanoma. |
therapeutic application
unassigned |
3
0 |
| 3.4.24.46 | Melanoma |
23649038 |
Biological Properties of Melanoma and Endothelial Cells after Plasmid AMEP Gene Electrotransfer Depend on Integrin Quantity on Cells. |
ongoing research
unassigned |
4
0 |
| 3.4.24.46 | Neoplasms |
12621058 |
Characterization of growth factor-induced serine phosphorylation of tumor necrosis factor-alpha converting enzyme and of an alternatively translated polypeptide. |
ongoing research
unassigned |
2
0 |
| 3.4.24.46 | Purpura, Thrombotic Thrombocytopenic |
23743117 |
Complement activation in diseases presenting with thrombotic microangiopathy. |
causal interaction
therapeutic application
unassigned |
1
1
0 |
| 3.4.24.46 | Melanoma |
25781650 |
Gene electrotransfer of plasmid AMEP, an integrin-targeted therapy, has antitumor and antiangiogenic action in murine B16 melanoma. |
causal interaction
therapeutic application
unassigned |
4
4
0 |
| 3.4.24.46 | Melanoma |
23980876 |
Gene Electrotransfer of Plasmid Antiangiogenic Metargidin Peptide (AMEP) in Disseminated Melanoma: Safety and Efficacy Results of a Phase I First-in-Man Study. |
therapeutic application
unassigned |
2
0 |
| 3.4.24.46 | Adenocarcinoma |
11708814 |
Inhibitory antibodies against endopeptidase activity of human adamalysin 19. |
causal interaction
diagnostic usage
ongoing research
unassigned |
2
2
3
0 |
| 3.4.24.46 | Osteoarthritis |
33381768 |
Interleukin 13 (IL-13)-regulated expression of the chondroprotective metalloproteinase ADAM15 is reduced in aging cartilage. |
diagnostic usage
ongoing research
therapeutic application
unassigned |
1
4
4
0 |
